LYRA THERAPEUTICS INC (LYRA) Stock Price, Quote, News and Overview
NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD
LYRA Quote, Performance and Key Statistics
NASDAQ:LYRA (2/24/2025, 12:05:50 PM)
0.2067
+0 (+0.49%)
The current stock price of LYRA is 0.2067 USD. In the past month the price increased by 10.41%. In the past year, price decreased by -96.12%.
LYRA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 68.15 | 841.10B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28 | 398.92B | ||
| JNJ | JOHNSON & JOHNSON | 16.4 | 394.50B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.74 | 232.18B | ||
| MRK | MERCK & CO. INC. | 11.98 | 231.44B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.82 | 216.69B | ||
| PFE | PFIZER INC | 8.5 | 149.76B | ||
| SNY | SANOFI-ADR | 13.48 | 135.56B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.4 | 116.53B | ||
| GSK | GSK PLC-SPON ADR | 7.87 | 75.69B | ||
| ZTS | ZOETIS INC | 27.69 | 73.95B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.16 | 44.86B |
Related stock screener links
About LYRA
Company Profile
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.
Company Info
LYRA THERAPEUTICS INC
480 Arsenal Way
Watertown MASSACHUSETTS 02472 US
CEO: Maria Palasis
Employees: 109
Company Website: https://lyratherapeutics.com/
Phone: 16173734600
LYRA THERAPEUTICS INC / LYRA FAQ
What is the stock price of LYRA THERAPEUTICS INC today?
The current stock price of LYRA is 0.2067 USD. The price increased by 0.49% in the last trading session.
What is the ticker symbol for LYRA THERAPEUTICS INC stock?
The exchange symbol of LYRA THERAPEUTICS INC is LYRA and it is listed on the Nasdaq exchange.
On which exchange is LYRA stock listed?
LYRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LYRA THERAPEUTICS INC stock?
9 analysts have analysed LYRA and the average price target is 1.27 USD. This implies a price increase of 516.84% is expected in the next year compared to the current price of 0.2067. Check the LYRA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LYRA THERAPEUTICS INC worth?
LYRA THERAPEUTICS INC (LYRA) has a market capitalization of 13.53M USD. This makes LYRA a Nano Cap stock.
How many employees does LYRA THERAPEUTICS INC have?
LYRA THERAPEUTICS INC (LYRA) currently has 109 employees.
What are the support and resistance levels for LYRA THERAPEUTICS INC (LYRA) stock?
LYRA THERAPEUTICS INC (LYRA) has a support level at 0.2 and a resistance level at 0.27. Check the full technical report for a detailed analysis of LYRA support and resistance levels.
Is LYRA THERAPEUTICS INC (LYRA) expected to grow?
The Revenue of LYRA THERAPEUTICS INC (LYRA) is expected to decline by -12.05% in the next year. Check the estimates tab for more information on the LYRA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LYRA THERAPEUTICS INC (LYRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LYRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LYRA, evaluating the profitability, health, valuation and growth aspects
- LYRA THERAPEUTICS INC (LYRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LYRA THERAPEUTICS INC (LYRA) Sales and EPS estimates to see what analysts future expectations are.
- LYRA THERAPEUTICS INC (LYRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LYRA THERAPEUTICS INC (LYRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- LYRA THERAPEUTICS INC (LYRA) Stock Chart to make your own analysis
- LYRA THERAPEUTICS INC (LYRA) Latest news and press-releases to stay up to date.
Does LYRA THERAPEUTICS INC (LYRA) stock pay dividends?
LYRA does not pay a dividend.
When does LYRA THERAPEUTICS INC (LYRA) report earnings?
LYRA THERAPEUTICS INC (LYRA) will report earnings on 2025-03-05, after the market close.
What is the Price/Earnings (PE) ratio of LYRA THERAPEUTICS INC (LYRA)?
LYRA THERAPEUTICS INC (LYRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.49).
What is the Short Interest ratio of LYRA THERAPEUTICS INC (LYRA) stock?
The outstanding short interest for LYRA THERAPEUTICS INC (LYRA) is 4.22% of its float. Check the ownership tab for more information on the LYRA short interest.
LYRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LYRA. When comparing the yearly performance of all stocks, LYRA is a bad performer in the overall market: 94.64% of all stocks are doing better.
LYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LYRA. LYRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LYRA Financial Highlights
Over the last trailing twelve months LYRA reported a non-GAAP Earnings per Share(EPS) of -1.49. The EPS decreased by -5.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.94% | ||
| ROE | -473.41% | ||
| Debt/Equity | 0 |
LYRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to LYRA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -8.32% and a revenue growth -12.05% for LYRA